These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32151645)

  • 1. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study.
    Sloan SE; Szretter KJ; Sundaresh B; Narayan KM; Smith PF; Skurnik D; Bedard S; Trevejo JM; Oldach D; Shriver Z
    Antiviral Res; 2020 Dec; 184():104763. PubMed ID: 32151645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
    Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D
    EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks.
    Wollacott AM; Boni MF; Szretter KJ; Sloan SE; Yousofshahi M; Viswanathan K; Bedard S; Hay CA; Smith PF; Shriver Z; Trevejo JM
    EBioMedicine; 2016 Mar; 5():147-55. PubMed ID: 27077121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
    McBride JM; Lim JJ; Burgess T; Deng R; Derby MA; Maia M; Horn P; Siddiqui O; Sheinson D; Chen-Harris H; Newton EM; Fillos D; Nazzal D; Rosenberger CM; Ohlson MB; Lambkin-Williams R; Fathi H; Harris JM; Tavel JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.
    Lim JJ; Derby MA; Zhang Y; Deng R; Larouche R; Anderson M; Maia M; Carrier S; Pelletier I; Girard J; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
    Trevejo JM; Asmal M; Vingerhoets J; Polo R; Robertson S; Jiang Y; Kieffer TL; Leopold L
    Antivir Ther; 2018; 23(4):335-344. PubMed ID: 29244026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.
    Ramos EL; Mitcham JL; Koller TD; Bonavia A; Usner DW; Balaratnam G; Fredlund P; Swiderek KM
    J Infect Dis; 2015 Apr; 211(7):1038-44. PubMed ID: 25281755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival during influenza-associated bacterial superinfection improves following viral- and bacterial-specific monoclonal antibody treatment.
    Robinson KM; Ramanan K; Tobin JM; Nickolich KL; Pilewski MJ; Kallewaard NL; Sellman BR; Cohen TS; Alcorn JF
    JCI Insight; 2019 Jul; 4(14):. PubMed ID: 31341107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.
    Baranovich T; Jones JC; Russier M; Vogel P; Szretter KJ; Sloan SE; Seiler P; Trevejo JM; Webby RJ; Govorkova EA
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2118-31. PubMed ID: 26787699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies.
    Vigil A; Frias-Staheli N; Carabeo T; Wittekind M
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A broadly neutralizing human monoclonal antibody is effective against H7N9.
    Tharakaraman K; Subramanian V; Viswanathan K; Sloan S; Yen HL; Barnard DL; Leung YH; Szretter KJ; Koch TJ; Delaney JC; Babcock GJ; Wogan GN; Sasisekharan R; Shriver Z
    Proc Natl Acad Sci U S A; 2015 Sep; 112(35):10890-5. PubMed ID: 26283346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans.
    Watson JM; Francis JN; Mesens S; Faiman GA; Makin J; Patriarca P; Treanor JJ; Georges B; Bunce CJ
    Virol J; 2015 Feb; 12():13. PubMed ID: 25645025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection.
    Lim JJ; Nilsson AC; Silverman M; Assy N; Kulkarni P; McBride JM; Deng R; Li C; Yang X; Nguyen A; Horn P; Maia M; Castro A; Peck MC; Galanter J; Chu T; Newton EM; Tavel JA
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32393496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous peramivir for treatment of influenza in hospitalized patients.
    Ison MG; Fraiz J; Heller B; Jauregui L; Mills G; O'Riordan W; O'Neil B; Playford EG; Rolf JD; Sada-Diaz E; Elder J; Collis P; Hernandez JE; Sheridan WP
    Antivir Ther; 2014; 19(4):349-61. PubMed ID: 23985625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
    Leyva-Grado VH; Tan GS; Leon PE; Yondola M; Palese P
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4162-72. PubMed ID: 25941218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
    Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study.
    Yogaratnam J; Rito J; Kakuda TN; Fennema H; Gupta K; Jekle CA; Mitchell T; Boyce M; Sahgal O; Balaratnam G; Chanda S; Van Remoortere P; Symons JA; Fry J
    J Infect Dis; 2019 Jan; 219(2):177-185. PubMed ID: 30053042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Level Antibody Response to Pandemic Influenza H1N1/09 Virus Is Associated With Interferon-Induced Transmembrane Protein-3 rs12252-CC in Young Adults.
    Qin L; Wang D; Li D; Zhao Y; Peng Y; Wellington D; Dai Y; Sun H; Sun J; Liu G; McMichael A; Dong T; Zhang Y
    Front Cell Infect Microbiol; 2018; 8():134. PubMed ID: 29868492
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.